171 related articles for article (PubMed ID: 36508705)
21. Chromosomal Abnormalities and Prognosis in
Angenendt L; Röllig C; Montesinos P; Martínez-Cuadrón D; Barragan E; García R; Botella C; Martínez P; Ravandi F; Kadia T; Kantarjian HM; Cortes J; Juliusson G; Lazarevic V; Höglund M; Lehmann S; Recher C; Pigneux A; Bertoli S; Dumas PY; Dombret H; Preudhomme C; Micol JB; Terré C; Ráčil Z; Novák J; Žák P; Wei AH; Tiong IS; Wall M; Estey E; Shaw C; Exeler R; Wagenführ L; Stölzel F; Thiede C; Stelljes M; Lenz G; Mikesch JH; Serve H; Ehninger G; Berdel WE; Kramer M; Krug U; Schliemann C
J Clin Oncol; 2019 Oct; 37(29):2632-2642. PubMed ID: 31430225
[TBL] [Abstract][Full Text] [Related]
22. Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML.
Narayanan D; Pozdnyakova O; Hasserjian RP; Patel SS; Weinberg OK
Blood Adv; 2021 Jun; 5(11):2539-2549. PubMed ID: 34100902
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Relevance of DNMT3A, FLT3 and NPM1 Mutations in Syrian Acute Myeloid Leukemia Patients.
Moualla Y; Moassass F; Al-Halbi B; Al-Achkar W; Georgeos M; Yazigi H; Khamis A
Asian Pac J Cancer Prev; 2022 Apr; 23(4):1387-1395. PubMed ID: 35485701
[TBL] [Abstract][Full Text] [Related]
24. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
Lachowiez CA; Reville PK; Kantarjian H; Jabbour E; Borthakur G; Daver N; Issa G; Furudate K; Tanaka T; Pierce S; Tang G; Patel KP; Medeiros J; Abbas HA; Haddad F; Hammond D; Short NJ; Maiti A; Yilmaz M; Sasaki K; Takahashi K; Pemmaraju N; Konopleva M; Garcia-Manero G; Ravandi F; Kadia TM; Loghavi S; DiNardo CD
Am J Hematol; 2022 Nov; 97(11):1443-1452. PubMed ID: 36054614
[TBL] [Abstract][Full Text] [Related]
25. NPM1-mutated acute myeloid leukemia: from bench to bedside.
Falini B; Brunetti L; Sportoletti P; Martelli MP
Blood; 2020 Oct; 136(15):1707-1721. PubMed ID: 32609823
[TBL] [Abstract][Full Text] [Related]
26. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?
Falini B; Martelli MP; Bolli N; Sportoletti P; Liso A; Tiacci E; Haferlach T
Blood; 2011 Jan; 117(4):1109-20. PubMed ID: 21030560
[TBL] [Abstract][Full Text] [Related]
27. [Association of Next Generation Sequencing Based Genotypic Profiling with MICM Characteristics in NPM1 Mutated Acute Myeloid Leukemia].
Wang B; Ling Y; Dai L; Gu WY; Zhang XW; Xing SS; Li HQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):56-60. PubMed ID: 35123604
[TBL] [Abstract][Full Text] [Related]
28. Current status and future perspectives in targeted therapy of NPM1-mutated AML.
Ranieri R; Pianigiani G; Sciabolacci S; Perriello VM; Marra A; Cardinali V; Pierangeli S; Milano F; Gionfriddo I; Brunetti L; Martelli MP; Falini B
Leukemia; 2022 Oct; 36(10):2351-2367. PubMed ID: 36008542
[TBL] [Abstract][Full Text] [Related]
29. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
Dufour A; Schneider F; Hoster E; Benthaus T; Ksienzyk B; Schneider S; Kakadia PM; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Subklewe M; Hiddemann W; Bohlander SK; Spiekermann K;
Ann Hematol; 2012 Jul; 91(7):1051-63. PubMed ID: 22362118
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.
Röllig C; Bornhäuser M; Kramer M; Thiede C; Ho AD; Krämer A; Schäfer-Eckart K; Wandt H; Hänel M; Einsele H; Aulitzky WE; Schmitz N; Berdel WE; Stelljes M; Müller-Tidow C; Krug U; Platzbecker U; Wermke M; Baldus CD; Krause SW; Stölzel F; von Bonin M; Schaich M; Serve H; Schetelig J; Ehninger G
J Clin Oncol; 2015 Feb; 33(5):403-10. PubMed ID: 25547501
[TBL] [Abstract][Full Text] [Related]
31. High
Patel SS; Kuo FC; Gibson CJ; Steensma DP; Soiffer RJ; Alyea EP; Chen YA; Fathi AT; Graubert TA; Brunner AM; Wadleigh M; Stone RM; DeAngelo DJ; Nardi V; Hasserjian RP; Weinberg OK
Blood; 2018 Jun; 131(25):2816-2825. PubMed ID: 29724895
[TBL] [Abstract][Full Text] [Related]
32. Novel mutations of the nucleophosmin (NPM-1) gene in Egyptian patients with acute myeloid leukemia: a pilot study.
Kassem N; Hamid AA; Attia T; Baathallah S; Mahmoud S; Moemen E; Safwat E; Khalaf M; Shaker O
J Egypt Natl Canc Inst; 2011 Jun; 23(2):73-8. PubMed ID: 22099964
[TBL] [Abstract][Full Text] [Related]
33. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.
Schnittger S; Schoch C; Kern W; Mecucci C; Tschulik C; Martelli MF; Haferlach T; Hiddemann W; Falini B
Blood; 2005 Dec; 106(12):3733-9. PubMed ID: 16076867
[TBL] [Abstract][Full Text] [Related]
34. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Wu YZ; Schwind S; Paschka P; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
J Clin Oncol; 2010 Feb; 28(4):596-604. PubMed ID: 20026798
[TBL] [Abstract][Full Text] [Related]
35. The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype.
Schneider F; Hoster E; Unterhalt M; Schneider S; Dufour A; Benthaus T; Mellert G; Zellmeier E; Kakadia PM; Bohlander SK; Feuring-Buske M; Buske C; Braess J; Heinecke A; Sauerland MC; Berdel WE; Büchner T; Wörmann BJ; Hiddemann W; Spiekermann K
Blood; 2012 May; 119(19):4383-6. PubMed ID: 22374696
[TBL] [Abstract][Full Text] [Related]
36. Acute myeloid leukemia with mutated NPM1 mimics acute promyelocytic leukemia presentation.
Arana Rosainz MJ; Nguyen N; Wahed A; Lelenwa LC; Aakash N; Schaefer K; Rios A; Kanaan Z; Chen L
Int J Lab Hematol; 2021 Apr; 43(2):218-226. PubMed ID: 33099879
[TBL] [Abstract][Full Text] [Related]
37. The effect of small molecule inhibitor NSC348884 on nucleophosmin 1-mutated acute myeloid leukemia cells.
Zhu JF; Han LL; Ma Y; Wang YX; Zhang F
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(19):9145-9151. PubMed ID: 37843328
[TBL] [Abstract][Full Text] [Related]
38. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
[TBL] [Abstract][Full Text] [Related]
39. Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant.
El Hussein S; DiNardo CD; Takahashi K; Khoury JD; Fang H; Furudate K; Lyapichev KA; Garces S; Kanagal-Shamanna R; Ok CY; Patel KP; Routbort MJ; Ravandi F; Medeiros LJ; Wang SA; Loghavi S
Bone Marrow Transplant; 2022 Mar; 57(3):370-376. PubMed ID: 34992253
[TBL] [Abstract][Full Text] [Related]
40. The clinicopathologic significance of NPM1 mutation and ability to detect mutated NPM1 by immunohistochemistry in non-AML myeloid neoplasms.
Kaseb H; Visconte V; Socha DS; Crane GM; Durkin L; Cook JR; Maciejewski JP; Hsi ED; Rogers HJ
Genes Chromosomes Cancer; 2023 Oct; 62(10):573-580. PubMed ID: 36959701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
